Barclays analyst Luke Sergott lowered the firm’s price target on Bruker to $65 from $69 and keeps an Overweight rating on the shares. The firm ...
In a report released today, Brandon Couillard from Wells Fargo maintained a Buy rating on Bruker (BRKR – Research Report), with a price target ...
Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2024 financial results before ...
18d
Hosted on MSNCALID Arm Growth to Support Bruker Shares Amid Macro IssuesBruker’s BRKR strong growth reflects its fundamental commitment to innovate high-value solutions and its ongoing portfolio transformation. Yet, the company’s operations face the wrath of excessive ...
Shares of companies in the lab-tool equipment sector, including Bruker (NASDAQ:BRKR), Illumina (NASDAQ:ILMN), Quanterix ...
13d
News Medical on MSNBruker launches infrared imaging microscope for pharma and life science researchBruker Corporation announced the launch of the LUMOSâ„¢ II ILIM , a quantum cascade laser (QCL) based infrared imaging ...
timsTOF was engineered by Bruker experts as an open platform to accelerate the adoption of ion mobility-mass spectrometry analysis across research applications. All that is missing are your ...
4d
AZoM on MSNBruker Launches the VERTEX NEO PlatformBruker Corporation today announced the launch of the VERTEX NEO Platform today with its first product, the VERTEX NEO R. This ...
Bruker Corporation (NASDAQ: BRKR) is undervalued, trading below its fair value of $74, offering significant upside potential due to its strategic acquisitions and improving book value per share.
Integration with Bruker’s MALDI Imaging methods enable multimodal imaging to characterize tissues with enhanced analytical depth. The LUMOS II ILIM can also be used for rapid pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results